Merry Jo Oursler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Merry Jo Oursler has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Anne Gingery
Department of Biochemistry and Molecular Biology, University of Minnesota, Duluth 55812, USA
1 shared publication- Aubie K. Shaw
Vanderbilt-Ingram Cancer Center, Nashville, TN
1 shared publication B. Lawrence Riggs
Departments of *Biochemistry and Molecular Biology and ‡Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905; and †Biology, Biochemistry, and Molecular Biology, and Medical Microbiology and Immunology Departments, University of Minnesota, Duluth MN 55812
1 shared publicationDavid Pascoe
Departments of *Biochemistry and Molecular Biology and ‡Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905; and †Biology, Biochemistry, and Molecular Biology, and Medical Microbiology and Immunology Departments, University of Minnesota, Duluth MN 55812
1 shared publication- Elizabeth W. Bradley
Stem Cell Institute, University of Minnesota
1 shared publication - Genevieve A. Woodard
Mayo Clinic, Department of Breast Imaging and Intervention , Rochester, MN
1 shared publication
Latest Publications
- 17 February 2004
- Published by Wiley in Journal of Cellular Physiology
- Vol. 200 (1) , 99-106
Roles of stromal cell RANKL, OPG, and M‐CSF expression in biphasic TGF‐β regulation of osteoclast differentiation
To better understand the complex roles of transforming growth factor‐beta (TGF‐β) in bone metabolism, we examined the impact of a range of TGF‐β concentrations on osteoclast differentiation. In co‐cultures of support cells and spleen or marrow osteoclast precursors, low TGF‐β concentrations stimulated while high concentrations inhibited differentiation. We investigated the influences of TGF‐β on macrophage colony stimulating factor (M‐CSF), receptor activator of NF‐κB ligand (RANKL), and osteoprotegerin (OPG) expression and found a dose dependent inhibition of M‐CSF expression. RANKL expression was elevated at low TGF‐β concentrations with a less dramatic increase in OPG. Addition of OPG blocked differentiation at the stimulatory TGF‐β dose. Thus, low TGF‐β concentrations elevated the RANKL/OPG ratio while high concentrations did not, supporting that, at low TGF‐β concentrations, there is sufficient M‐CSF and a high RANKL/OPG ratio to stimulate differentiation. At high TGF‐β concentrations, the RANKL/OPG ratio and M‐CSF expression were both repressed and there was no differentiation. We examined whether TGF‐β‐mediated repression of osteoclasts differentiation is due to these changes by adding M‐CSF and/or RANKL and did not observe any impact on differentiation repression. We studied direct TGF‐β impacts on osteoclast precursors by culturing spleen or marrow cells with M‐CSF and RANKL. TGF‐β treatment dose‐dependently stimulated osteoclast differentiation. These data indicate that low TGF‐β levels stimulate osteoclast differentiation by impacting the RANKL/OPG ratio while high TGF‐β levels repress osteoclast differentiation by multiple avenues including mechanisms independent of the RANKL/OPG ratio or M‐CSF expression regulation.
- 17 February 2004
- Published by Wiley in Journal of Cellular Physiology
- Vol. 200 (1) , 99-106
Roles of stromal cell RANKL, OPG, and M‐CSF expression in biphasic TGF‐β regulation of osteoclast differentiation
To better understand the complex roles of transforming growth factor‐beta (TGF‐β) in bone metabolism, we examined the impact of a range of TGF‐β concentrations on osteoclast differentiation. In co‐cultures of support cells and spleen or marrow osteoclast precursors, low TGF‐β concentrations stimulated while high concentrations inhibited differentiation. We investigated the influences of TGF‐β on macrophage colony stimulating factor (M‐CSF), receptor activator of NF‐κB ligand (RANKL), and osteoprotegerin (OPG) expression and found a dose dependent inhibition of M‐CSF expression. RANKL expression was elevated at low TGF‐β concentrations with a less dramatic increase in OPG. Addition of OPG blocked differentiation at the stimulatory TGF‐β dose. Thus, low TGF‐β concentrations elevated the RANKL/OPG ratio while high concentrations did not, supporting that, at low TGF‐β concentrations, there is sufficient M‐CSF and a high RANKL/OPG ratio to stimulate differentiation. At high TGF‐β concentrations, the RANKL/OPG ratio and M‐CSF expression were both repressed and there was no differentiation. We examined whether TGF‐β‐mediated repression of osteoclasts differentiation is due to these changes by adding M‐CSF and/or RANKL and did not observe any impact on differentiation repression. We studied direct TGF‐β impacts on osteoclast precursors by culturing spleen or marrow cells with M‐CSF and RANKL. TGF‐β treatment dose‐dependently stimulated osteoclast differentiation. These data indicate that low TGF‐β levels stimulate osteoclast differentiation by impacting the RANKL/OPG ratio while high TGF‐β levels repress osteoclast differentiation by multiple avenues including mechanisms independent of the RANKL/OPG ratio or M‐CSF expression regulation.
- 2 April 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 89 (1) , 165-179
Phosphatidylinositol 3‐kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival
We have examined highly purified osteoclasts that were generated in vitro from murine co‐culture of marrow precursors with stromal support cells and have found evidence of activation of the MEK/ERK and AKT/NFκB survival pathways. Many mature marrow‐derived osteoclasts survived for at least 48 h in culture whether or not they are maintained with stromal cells. Moreover, supplementing purified osteoclasts with RANKL and/or M‐CSF had no impact on their survival pattern. In addition, spleen‐derived osteoclasts generated with RANKL and M‐CSF treatment exhibited a similar survival pattern. Blocking MEK, AKT, or NFκB activity resulted in apoptosis of many, but not all, of the osteoclasts in purified marrow‐derived osteoclasts, marrow‐derived osteoclasts co‐cultured with stromal cells, and spleen‐derived osteoclasts maintained with RANKL and M‐CSF. These data support that both the MEK/ERK and AKT/NFκB pathways contribute to osteoclast survival. Since PI3K has been shown to activate either of these pathways, we have examined its role in osteoclast survival. PI3K inhibition caused apoptosis of nearly all osteoclasts in purified and co‐cultured marrow‐derived osteoclasts and spleen‐derived osteoclasts maintained with RANKL and M‐CSF. Interestingly, in marrow‐derived co‐cultures, the apoptotic response was restricted to osteoclasts as there was no evidence of stromal support cell apoptosis. PI3K inhibition also blocked MEK1/2, ERK1/2, and AKT phosphorylation and NFκB activation in purified osteoclasts. Simultaneous blockage of both AKT and MEK1/2 caused rapid apoptosis of nearly all osteoclasts, mimicking the response to PI3K inhibition. These data reveal that PI3K coordinately activates two distinct survival pathways that are both important in osteoclast survival. J. Cell. Biochem. 89: 165–179, 2003.
- 2 April 2003
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 89 (1) , 165-179
Phosphatidylinositol 3‐kinase coordinately activates the MEK/ERK and AKT/NFκB pathways to maintain osteoclast survival
We have examined highly purified osteoclasts that were generated in vitro from murine co‐culture of marrow precursors with stromal support cells and have found evidence of activation of the MEK/ERK and AKT/NFκB survival pathways. Many mature marrow‐derived osteoclasts survived for at least 48 h in culture whether or not they are maintained with stromal cells. Moreover, supplementing purified osteoclasts with RANKL and/or M‐CSF had no impact on their survival pattern. In addition, spleen‐derived osteoclasts generated with RANKL and M‐CSF treatment exhibited a similar survival pattern. Blocking MEK, AKT, or NFκB activity resulted in apoptosis of many, but not all, of the osteoclasts in purified marrow‐derived osteoclasts, marrow‐derived osteoclasts co‐cultured with stromal cells, and spleen‐derived osteoclasts maintained with RANKL and M‐CSF. These data support that both the MEK/ERK and AKT/NFκB pathways contribute to osteoclast survival. Since PI3K has been shown to activate either of these pathways, we have examined its role in osteoclast survival. PI3K inhibition caused apoptosis of nearly all osteoclasts in purified and co‐cultured marrow‐derived osteoclasts and spleen‐derived osteoclasts maintained with RANKL and M‐CSF. Interestingly, in marrow‐derived co‐cultures, the apoptotic response was restricted to osteoclasts as there was no evidence of stromal support cell apoptosis. PI3K inhibition also blocked MEK1/2, ERK1/2, and AKT phosphorylation and NFκB activation in purified osteoclasts. Simultaneous blockage of both AKT and MEK1/2 caused rapid apoptosis of nearly all osteoclasts, mimicking the response to PI3K inhibition. These data reveal that PI3K coordinately activates two distinct survival pathways that are both important in osteoclast survival. J. Cell. Biochem. 89: 165–179, 2003.
- Open Access
- 19 January 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (2) , 505-510
Androgens regulate bone resorption activity of isolated osteoclastsin vitro
For many years it has been recognized that sex steroids have profound effects on bone metabolism. The current perception is that estrogen decreases bone resorption and androgen increases bone deposition. To investigate the potential for androgens to directly modulate bone resorption, we have examined avian osteoclast and human and mouse osteoclast-like cells for androgen responsiveness. There was a dose-dependent decrease in resorption activity in response to α-dihydrotestosterone (α-DHT), β-DHT, testosterone, or the synthetic androgen RU1881. This decrease was blocked by cotreatment with the specific androgen antagonist hydroxyflutamide. Further examination of avian osteoclasts revealed that the cells exhibited specific and saturable nuclear binding of tritiated RU1881 and that α-DHT stimulated the activity of the androgen response element as measured by using a chloramphenicol acetyltransferase reporter plasmid. In addition, avian osteoclasts responded to androgen treatment with elevated production and secretion of transforming growth factor β, a well documented response to androgen exposure in other cell systems. Treatment with either α-DHT or β-DHT for 24 hours resulted in a significant dose-dependent decrease in secretion of cathepsin B and tartrate-resistant acid phosphatase. This response to β-DHT, a stereoisomer of α-DHT that is inactive in other androgen receptor-dependent systems, supports the hypothesis that the osteoclast androgen receptor has unusual ligand-binding properties. Taken together, these results confirm the presence of functional androgen receptors in these cells and support the conclusion that osteoclasts are able to respond directly to androgensin vitroand thus are potential androgen target cellsin vivo.
- 19 January 1999
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (2) , 505-510
Open AccessAndrogens regulate bone resorption activity of isolated osteoclastsin vitro
For many years it has been recognized that sex steroids have profound effects on bone metabolism. The current perception is that estrogen decreases bone resorption and androgen increases bone deposition. To investigate the potential for androgens to directly modulate bone resorption, we have examined avian osteoclast and human and mouse osteoclast-like cells for androgen responsiveness. There was a dose-dependent decrease in resorption activity in response to α-dihydrotestosterone (α-DHT), β-DHT, testosterone, or the synthetic androgen RU1881. This decrease was blocked by cotreatment with the specific androgen antagonist hydroxyflutamide. Further examination of avian osteoclasts revealed that the cells exhibited specific and saturable nuclear binding of tritiated RU1881 and that α-DHT stimulated the activity of the androgen response element as measured by using a chloramphenicol acetyltransferase reporter plasmid. In addition, avian osteoclasts responded to androgen treatment with elevated production and secretion of transforming growth factor β, a well documented response to androgen exposure in other cell systems. Treatment with either α-DHT or β-DHT for 24 hours resulted in a significant dose-dependent decrease in secretion of cathepsin B and tartrate-resistant acid phosphatase. This response to β-DHT, a stereoisomer of α-DHT that is inactive in other androgen receptor-dependent systems, supports the hypothesis that the osteoclast androgen receptor has unusual ligand-binding properties. Taken together, these results confirm the presence of functional androgen receptors in these cells and support the conclusion that osteoclasts are able to respond directly to androgensin vitroand thus are potential androgen target cellsin vivo.